JP2007509981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509981A5 JP2007509981A5 JP2006538369A JP2006538369A JP2007509981A5 JP 2007509981 A5 JP2007509981 A5 JP 2007509981A5 JP 2006538369 A JP2006538369 A JP 2006538369A JP 2006538369 A JP2006538369 A JP 2006538369A JP 2007509981 A5 JP2007509981 A5 JP 2007509981A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- composition according
- polysaccharide
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000002105 nanoparticle Substances 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 150000004676 glycans Chemical class 0.000 claims 19
- 229920001282 polysaccharide Polymers 0.000 claims 19
- 239000005017 polysaccharide Substances 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 16
- 102000003886 Glycoproteins Human genes 0.000 claims 15
- 108090000288 Glycoproteins Proteins 0.000 claims 15
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 11
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 11
- 229960003776 glatiramer acetate Drugs 0.000 claims 11
- 239000002202 Polyethylene glycol Substances 0.000 claims 7
- 239000000194 fatty acid Substances 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 239000001993 wax Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 238000002844 melting Methods 0.000 claims 5
- 230000008018 melting Effects 0.000 claims 5
- 150000003626 triacylglycerols Chemical class 0.000 claims 5
- 230000007515 enzymatic degradation Effects 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004530 micro-emulsion Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- -1 polyoxy Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims 1
- 229960000878 docusate sodium Drugs 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000005809 transesterification reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51632403P | 2003-10-31 | 2003-10-31 | |
| PCT/US2004/036172 WO2005041933A1 (en) | 2003-10-31 | 2004-10-28 | Nanoparticles for drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509981A JP2007509981A (ja) | 2007-04-19 |
| JP2007509981A5 true JP2007509981A5 (enExample) | 2007-12-13 |
Family
ID=34549527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538369A Withdrawn JP2007509981A (ja) | 2003-10-31 | 2004-10-28 | 薬物デリバリー用ナノ粒子 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050170004A1 (enExample) |
| EP (1) | EP1680087A1 (enExample) |
| JP (1) | JP2007509981A (enExample) |
| KR (1) | KR20060097020A (enExample) |
| AU (1) | AU2004285553B2 (enExample) |
| CA (1) | CA2541445A1 (enExample) |
| EA (1) | EA200600877A1 (enExample) |
| IL (1) | IL174748A0 (enExample) |
| NZ (1) | NZ546379A (enExample) |
| WO (1) | WO2005041933A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE60237170D1 (de) * | 2001-12-04 | 2010-09-09 | Teva Pharma | Verfahren zur messung der wirkstärke von glatirameracetat |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| SG186686A1 (en) * | 2004-06-25 | 2013-01-30 | Id Biomedical Corp Quebec | Compositions and methods for treating neurological disorders |
| WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US8324641B2 (en) * | 2007-06-29 | 2012-12-04 | Ledengin, Inc. | Matrix material including an embedded dispersion of beads for a light-emitting device |
| NZ556156A (en) * | 2005-02-02 | 2010-03-26 | Teva Pharma | Process for producing acetate salts of polypeptides using hydrogenolysis |
| EP1891233A4 (en) * | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| DE102005044400A1 (de) * | 2005-09-16 | 2007-03-22 | Capsulution Nanoscience Ag | Verfahren zur Verkapselung und kontrollierten Freisetzung von schwer wasserlöslichen (hydrophoben) flüssigen und festen Wirkstoffen |
| EP2061583B1 (en) * | 2006-09-14 | 2019-04-10 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Organic nanoparticles obtained from microemulsions by solvent evaporation |
| AR063704A1 (es) | 2006-09-14 | 2009-02-11 | Makhteshim Chem Works Ltd | Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones |
| WO2008121926A1 (en) | 2007-03-30 | 2008-10-09 | Particle Sciences, Inc. | Particle formulations and uses thereof |
| AU2008330093A1 (en) * | 2007-11-28 | 2009-06-04 | Yeda Research And Development Co., Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| US9060932B2 (en) | 2009-07-09 | 2015-06-23 | Oshadi Drug Administration Ltd. | Matrix carrier compositions, methods and uses |
| ES2351756B1 (es) * | 2009-07-28 | 2011-10-05 | Universidad Del Pais Vasco | Nanopartículas lipídicas para terapia génica. |
| UA103699C2 (ru) | 2009-08-20 | 2013-11-11 | Еда Рисёрч Энд Девелопмент Ко., Лтд. | Терапия глатирамера ацетатом с низкой частотой |
| EP2482818A4 (en) * | 2009-09-29 | 2014-04-09 | Eyegate Pharmaceuticals Inc | POSITIVELY CHARGED POLY (D, L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND METHODS OF MAKING SAME |
| CA2784394C (en) | 2010-01-04 | 2016-12-13 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US20120039814A1 (en) * | 2010-08-13 | 2012-02-16 | Sample Jennifer L | Topical Compositions and Methods of Detection and Treatment |
| US10758630B2 (en) * | 2010-08-13 | 2020-09-01 | The Johns Hopkins University | Topical compositions and methods of detection and treatment |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| CA2851510A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| TWI483747B (zh) * | 2012-05-29 | 2015-05-11 | Univ Nat Chiao Tung | 口服式藥物載體及其製備方法 |
| US9724304B2 (en) * | 2012-06-14 | 2017-08-08 | Temple University—Of the Commonwealth System of Higher Education | Nanospheres for therapeutic agent delivery |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| EP2914247A4 (en) * | 2012-10-30 | 2016-06-29 | Particle Sciences Inc | DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING ELEMENTS |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015140790A1 (en) * | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| BR112018067485A2 (pt) * | 2016-03-01 | 2019-02-12 | Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca | sistema para tratamento por termoterapia ou prevenção de infecções resistentes a antimicrobianos ou por biofilme |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| US12370233B2 (en) | 2016-08-31 | 2025-07-29 | Mapi Pharma Ltd. | Depot systems comprising glatiramer acetate |
| US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
| WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| CN117120070B (zh) * | 2021-03-11 | 2024-11-15 | 89生物公司 | 包含突变型fgf-21肽peg化缀合物的液体制剂 |
| CA3211539A1 (en) | 2021-03-11 | 2022-09-15 | Boris Schwartsburd | Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates |
| WO2023033900A1 (en) | 2021-09-06 | 2023-03-09 | Slayback Pharma Llc | Pharmaceutical compositions of mifepristone |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| AU658608B2 (en) * | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| ES2093562B1 (es) * | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| JP2001503735A (ja) * | 1996-07-03 | 2001-03-21 | ユニバーシティ オブ ピッツバーグ | 親水性活性試薬のためのエマルジョン処方物 |
| US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US20030170313A1 (en) * | 1997-10-09 | 2003-09-11 | Ales Prokop | Micro-particulate and nano-particulate polymeric delivery system |
| US7101575B2 (en) * | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
| DE69929959T2 (de) * | 1998-03-30 | 2006-11-02 | Jagotec Ag | Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung |
| DE19819273A1 (de) * | 1998-04-30 | 1999-11-11 | Pharmatec International S Giul | Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung |
| US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6355270B1 (en) * | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
| US6355271B1 (en) * | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| DE50013950D1 (de) * | 1999-05-07 | 2007-02-22 | Pharmasol Gmbh | Arzneistoffträger zur kontrollierten wirkstoffapplikation hergestellt aus lipidmatrix-arzneistoff-konjugaten (lak-partikel) |
| US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US7195780B2 (en) * | 2002-10-21 | 2007-03-27 | University Of Florida | Nanoparticle delivery system |
| US6482439B2 (en) * | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| DE10001172A1 (de) * | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templatieren von Feststoffpartikeln mit Polymermultischichten |
| ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| SE516555C2 (sv) * | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
| US6887493B2 (en) * | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
| SI1345597T1 (sl) * | 2000-12-27 | 2007-12-31 | Ares Trading Sa | Amfifilni lipidni nanodelci za vgradnjo peptidov in/ali proteinov |
| WO2003000236A1 (en) * | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particles with improved solubilization capacity |
| KR100566911B1 (ko) * | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
| US7125568B2 (en) * | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
| WO2003062372A2 (en) * | 2001-10-02 | 2003-07-31 | The Regents Of The University Of California | Nanoparticle assembled hollow spheres |
| US7311926B2 (en) * | 2002-12-20 | 2007-12-25 | Battelle Memorial Institute | Biocomposite materials and methods for making the same |
| WO2005048435A1 (de) * | 2003-11-13 | 2005-05-26 | Sew-Eurodrive Gmbh & Co. Kg | Kompaktantrieb |
| WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
-
2004
- 2004-10-28 EA EA200600877A patent/EA200600877A1/ru unknown
- 2004-10-28 US US10/977,926 patent/US20050170004A1/en not_active Abandoned
- 2004-10-28 WO PCT/US2004/036172 patent/WO2005041933A1/en not_active Ceased
- 2004-10-28 NZ NZ546379A patent/NZ546379A/en unknown
- 2004-10-28 EP EP04796839A patent/EP1680087A1/en not_active Withdrawn
- 2004-10-28 AU AU2004285553A patent/AU2004285553B2/en not_active Ceased
- 2004-10-28 KR KR1020067007794A patent/KR20060097020A/ko not_active Ceased
- 2004-10-28 CA CA002541445A patent/CA2541445A1/en not_active Abandoned
- 2004-10-28 JP JP2006538369A patent/JP2007509981A/ja not_active Withdrawn
-
2006
- 2006-04-03 IL IL174748A patent/IL174748A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509981A5 (enExample) | ||
| JP5672264B2 (ja) | 抗ヒトＴＮＦ−α抗体活性低下抑制剤 | |
| JP2007509981A (ja) | 薬物デリバリー用ナノ粒子 | |
| JPWO2019227085A5 (enExample) | ||
| JP2011511789A5 (enExample) | ||
| CA2526534A1 (en) | Compounds and methods for delivery of prostacyclin analogs | |
| Mahtab et al. | Facile functionalization of Teriflunomide-loaded nanoliposomes with Chondroitin sulphate for the treatment of Rheumatoid arthritis | |
| JP2003508439A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| JP2012012418A5 (enExample) | ||
| CN1197388A (zh) | 用于口服给药的药物组合物 | |
| JP4896220B2 (ja) | 肺疾患治療薬 | |
| JP2006522105A5 (enExample) | ||
| US20210220428A1 (en) | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
| TW202308661A (zh) | 寡核苷酸之口服遞送 | |
| JP2011520980A5 (enExample) | ||
| JP2009512699A5 (enExample) | ||
| JP2020518659A5 (enExample) | ||
| JP2013545802A5 (enExample) | ||
| JP2008522972A5 (enExample) | ||
| CN115006547A (zh) | 负载氯沙坦钾的响应性zif-8纳米颗粒及其制备方法和应用 | |
| ES2832300T3 (es) | Composición farmacéutica con agentes antiinflamatorios y proceso de producción | |
| de Souza Furtado et al. | In vivo evaluation of time-dependent antithrombotic effect of rivaroxaban-loaded poly (lactic-co-glycolic acid)/sodium lauryl sulfate or didodecyl dimethylammonium bromide nanoparticles in Wistar rats | |
| Gomez-Orellana et al. | Advances in the oral delivery of proteins | |
| KR20230058590A (ko) | 연어과 오일 조성물을 사용하는 호흡기 치료 |